一种低成本、经林业发展局批准的药物组合在临床前期测试中通过堵塞一条关键路径来扭转肝纤维化,为目前没有治疗的疾病带来希望。 A low-cost, FDA-approved drug combo reverses liver fibrosis in preclinical tests by blocking a key pathway, offering hope for a disease with no current treatment.

在临床初步研究中,以50:1的比例将硅碱和角化醇结合起来,通过协同抑制Wnt4/β-Catnin途径,显示出扭转肝纤维化的强烈前景。 A combination of silybin and carvedilol at a 50:1 ratio shows strong promise in reversing liver fibrosis in preclinical studies by synergistically inhibiting the Wnt4/β-catenin pathway. 这对药物组合已获得FDA批准且成本低廉，在减少纤维化和改善肝功能方面优于单次治疗和已知的实验性药物。 The drug pair, already FDA-approved and low-cost, outperformed single treatments and a known experimental drug in reducing fibrosis and improving liver function. 中国药学院2025年12月的一项研究发现，为一种无获批抗纤维化治疗的疾病提供了快速临床检测的途径。 The findings, from a December 2025 study by China Pharmaceutical University, offer a rapid path to clinical testing for a condition with no approved antifibrotic treatments.